H.C. Wainwright Raises the PT on uniQure N.V. (QURE), Keeps a Buy Rating

​uniQure N.V. (NASDAQ:QURE) is one of the Hot Growth Stocks to Invest in Now. On October 6, Patrick Trucchio from H.C. Wainwright raised the firm’s price target on uniQure N.V. (NASDAQ:QURE) from $70 to $110, while keeping a Buy rating on the stock.

The analyst based his bullish sentiment on the promising results from the company’s AMT-130 trials, which were released on September 24. The stock has surged more than 339% since the announcement. The all-important 3-year data from the drug’s phase 1/2 trials for Huntington’s disease demonstrated a significant slowdown in disease progression along with improvements in biomarkers. The analyst in his research note highlighted that these results suggest that AMT 130 has the potential to become the first treatment to alter the diseased natural course.

​uniQure N.V. (NASDAQ:QURE) specializes in gene therapy by developing one-time gene therapies aimed at potentially curing genetic and serious diseases.

While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.